Doyle Raizner Law Firm to Help Pradaxa Victims
Pradaxa has been placed on the list of drugs for severe or fatal complications. Doyle Raizner, a Houston personal injury law firm is reaching out to people affected by this drug.
Houston, Texas (PRWEB) July 07, 2012
Houston area law firm Doyle Raizner is reaching out to people who have taken Pradaxa, an anti-coagulant prescription drug that’s proving to have potentially fatal side effects. The firm, which frequently represents medical patients and the elderly in lawsuits involving unsafe drugs, decided to take action after the drug’s high fatality rate came to light earlier this month.
According to a report from the Institute for Safe Medication Practices, the United States Food and Drug Administration places Pradaxa on the top of the list of drugs with serious or fatal complications in 2011. For more information about the findings of the FDA, visit the Adverse Events Report for March of 2011. Pradaxa was developed to help prevent blood clots and thereby reduce the risk of stroke. But one of its most common and dangerous side effects is massive hemorrhaging, or even bleeding in the brain.
In Jeff Raizner’s experience as a personal injury attorney, he says “There’s a huge number of patients out there who take Pradaxa and don’t realize what kind of health threat it represents.”
Due to the way Pradaxa works, in the event of an adverse reaction or emergency there is no way for doctors to reverse its effects once it’s in the system, unlike its alternatives such as warfarin.
About Doyle Raizner LLP:
Doyle Raizner is a national personal injury litigation firm with main offices in Houston, Texas and Phoenix, Arizona. Doyle Raizner has worked on behalf of victims of unsafe drugs, including Pradaxa patients across the United States. The firm’s attorneys specialize in helping victims secure fair compensation for trauma, injuries or the death of a loved one. They can be contacted at 888-571-1001 or 713-571-1146, or by email at Jraizner(at)doyleraizner(dot)com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9664057.htm